CPE54

CPE54 is a 54-amino acid peptide derived from the C-terminal binding domain of the *Clostridium perfringens* enterotoxin (CPE). It is currently under development by IGF Oncology, which holds an exclusive license for the technology from Yale University and the University of Arkansas for Medical Sciences. CPE54 is designed to target Claudin-3 (CLDN3) and Claudin-4 (CLDN4), proteins that are integral components of tight junctions and are frequently overexpressed in epithelial malignancies, including ovarian, pancreatic, and breast cancers. Unlike the full-length enterotoxin, CPE54 lacks the N-terminal domain responsible for membrane pore formation and cell lysis, rendering it non-toxic. This makes it a suitable candidate for use as a targeting ligand to deliver therapeutic payloads, such as toxins or chemotherapy, or diagnostic imaging agents specifically to claudin-expressing tumor cells.

Other names

C-CPE54C-CPE-54C-CPE 54C-terminal Clostridium perfringens enterotoxin fragment